CAN
OCUL icon

Cetera Advisor Networks’s Ocular Therapeutix OCUL Stock Holding History

Cetera Advisor Networks’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,500
Closed -$12K – 2442
2020
Q2 		$12K Buy
+1,500
New +$9.94K ﹤0.01% 2644

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cetera Advisor Networks's OCUL Position: Q3 2020 in Review

Cetera Advisor Networks sold out of Ocular Therapeutix (OCUL) in Q3 2020, closing a stake of 1,500 shares — an estimated $12K sold.

Cetera Advisor Networks first reported a position in OCUL in Q2 2020 and held it in 1 quarter. The position peaked at $12K in Q2 2020. 108 funds tracked by Wall St. Rank hold OCUL as of Q3 2020.

  • Cetera Advisor Networks reported no remaining Ocular Therapeutix position as of Q3 2020 after selling out during the quarter.
  • Cetera Advisor Networks sold 1,500 Ocular Therapeutix shares in Q3 2020, an estimated $12K.
  • Cetera Advisor Networks first reported a position in Ocular Therapeutix in Q2 2020 and held it in 1 quarter.
  • Cetera Advisor Networks's Ocular Therapeutix position peaked at $12K in Q2 2020.
  • 108 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2020.

Based on Cetera Advisor Networks's 13F filing for Q3 2020, filed 13 Nov 2020.